Seroatlas · Human Serome Atlas

FAR1

Fatty acyl-CoA reductase 1

Also known as: FACR1_HUMAN, FLJ22728, MLSTD2, SDR10E1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q8WVX9
Gene
FAR1
Ensembl
ENSG00000197601
Chromosome
11
Canonical length
515 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location
Peroxisomes

OverviewNCBI Gene

The protein encoded by this gene is required for the reduction of fatty acids to fatty alcohols, a process that is required for the synthesis of monoesters and ether lipids. NADPH is required as a cofactor in this reaction, and 16-18 carbon saturated and unsaturated fatty acids are the preferred substrate. This is a peroxisomal membrane protein, and studies suggest that the N-terminus contains a large catalytic domain located on the outside of the peroxisome, while the C-terminus is exposed to the matrix of the peroxisome. Studies indicate that the regulation of this protein is dependent on plasmalogen levels. Mutations in this gene have been associated with individuals affected by severe intellectual disability, early-onset epilepsy, microcephaly, congenital cataracts, growth retardation, and spasticity (PMID: 25439727). A pseudogene of this gene is located on chromosome 13. [provided by RefSeq, Jan 2015]

Canonical amino-acid sequenceUniProt

515 residues, UniProt reviewed canonical sequence.

>Q8WVX9|FAR1
     1  MVSIPEYYEG KNVLLTGATG FLGKVLLEKL LRSCPKVNSV YVLVRQKAGQ TPQERVEEVL
    61  SGKLFDRLRD ENPDFREKII AINSELTQPK LALSEEDKEV IIDSTNIIFH CAATVRFNEN
   121  LRDAVQLNVI ATRQLILLAQ QMKNLEVFMH VSTAYAYCNR KHIDEVVYPP PVDPKKLIDS
   181  LEWMDDGLVN DITPKLIGDR PNTYIYTKAL AEYVVQQEGA KLNVAIVRPS IVGASWKEPF
   241  PGWIDNFNGP SGLFIAAGKG ILRTIRASNN ALADLVPVDV VVNMSLAAAW YSGVNRPRNI
   301  MVYNCTTGST NPFHWGEVEY HVISTFKRNP LEQAFRRPNV NLTSNHLLYH YWIAVSHKAP
   361  AFLYDIYLRM TGRSPRMMKT ITRLHKAMVF LEYFTSNSWV WNTENVNMLM NQLNPEDKKT
   421  FNIDVRQLHW AEYIENYCLG TKKYVLNEEM SGLPAARKHL NKLRNIRYGF NTILVILIWR
   481  IFIARSQMAR NIWYFVVSLC YKFLSYFRAS STMRY

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FAR1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Other membrane
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.24
Highest tissue expression
62 nTPM

Expression across tissuesHPA

Tissue

  • bone marrow: 62 nTPM
  • spinal cord: 58 nTPM
  • stomach: 54 nTPM
  • esophagus: 47 nTPM
  • duodenum: 34 nTPM
  • rectum: 32 nTPM

Single-cell type

  • neutrophils: 683 nCPM
  • neutrophil progenitors: 670 nCPM
  • foveolar cells: 433 nCPM
  • oligodendrocytes: 391 nCPM
  • mucous neck cells: 349 nCPM
  • late spermatids: 341 nCPM

Immune cell

  • neutrophil: 38 nTPM
  • myeloid DC: 27 nTPM
  • eosinophil: 26 nTPM
  • classical monocyte: 24 nTPM
  • intermediate monocyte: 20 nTPM
  • non-classical monocyte: 18 nTPM

Brain region

  • white matter: 174 nTPM
  • medulla oblongata: 104 nTPM
  • pons: 83 nTPM
  • spinal cord: 81 nTPM
  • cerebellum: 77 nTPM
  • basal ganglia: 77 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about FAR1.

Disease | AllUniProt

Conditions FAR1 is implicated in, by any mechanism.

Disease | GeneticClinVar

16 pathogenic / likely-pathogenic of 430 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.3
gnomAD pLI
0.99
gnomAD missense Z
3.3
DepMap mean gene effect
0.04
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of FAR1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FAR1 as an antibody target. Whether an autoantibody or antibody against FAR1 could matter depends on whether native FAR1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FAR1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label FAR1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/FAR1. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...